Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522677

Interdisciplinary Clinical Assessment and Management of Depressive Cognitive Disorders: Integrating Social Work, Nursing Practice, and Clinical Pathology in Patient-Centered Care

Khalid Mohammed S. Alshwikan [(1)] , Latifah Moner Albogami [(1)] , Zainab Ibrahim Saigh [(2)] , Nowayer Saad Sayed Alhaydal [(3)] , Tahani Ebrahim Ali Mabooj [(3)] , Ghada Ebrahim Ali Mabouj [(3)] , Ghina Ibrahim Ali Mabuj [(3)] , Maram Hussin Mohammed Banajiah [(4)]

(1) Alharam Hospital,Ministry of Health, Saudi Arabia,
(2) Mental Health Hospital,Ministry of Health, Saudi Arabia,
(3) Ministry of Health, Saudi Arabia,
(4) Irada Hospital for Mental Health,Ministry of Health, Saudi Arabia

Abstract

Background: Depressive cognitive disorder—historically termed pseudodementia—is a reversible or partially reversible cognitive impairment arising from underlying depressive or neuropsychiatric conditions. Its presentation often overlaps with neurodegenerative dementias, complicating diagnosis and delaying appropriate management.

Aim: This review aims to synthesize current evidence on the etiology, epidemiology, pathophysiology, clinical evaluation, and management of depressive cognitive disorders to support early recognition and improve interdisciplinary care.

Methods: A comprehensive analysis of contemporary clinical literature was performed, addressing neurochemical, structural, endocrine, genetic, and psychosocial contributors to depressive cognitive decline. The article integrates findings from neuropsychological testing frameworks, neuroimaging studies, and validated depression rating scales commonly used in older adults.

Results: Evidence indicates that depressive cognitive disorders stem from multifactorial mechanisms, including serotonergic dysfunction, hippocampal and amygdala abnormalities, HPA-axis hyperactivity, circadian disruption, maladaptive cognitive patterns, and psychosocial stress. Prevalence is high among older adults, with cognitive impairment present in up to 94% of patients during depressive episodes. Despite reversibility in many cases, up to 70% of individuals with depression-related cognitive impairment may progress to dementia over time. Effective management requires SSRIs or SNRIs as first-line therapies, complemented by ECT, psychotherapy, caregiver support, and lifestyle interventions.

Conclusion: Depressive cognitive disorder is a complex condition requiring multidimensional assessment and interprofessional management. Early identification and targeted treatment can improve cognitive and functional outcomes, though long-term prognosis varies.

Keywords: Depressive cognitive disorder; pseudodementia; major depressive disorder; cognitive impairment; geriatrics; neuropsychiatry; neurocognitive disorders; HPA axis; SSRIs; neuropsychology.

Introduction

Depressive cognitive disorder, historically referred to as pseudodementia, is a condition in which cognitive impairment arises secondary to neuropsychiatric disturbances and closely resembles the clinical presentation of primary neurodegenerative disease. The term pseudodementia was first introduced by Leslie Kiloh in 1961 to describe reversible cognitive deficits associated with depressive illness rather than structural brain pathology [1]. Despite advances in psychiatric and neurologic assessment, cognitive dysfunction attributable to depression and related mental disorders remains insufficiently recognized and frequently undertreated. Consequently, potentially reversible etiologies may be overlooked, leading to misdiagnosis and inappropriate management [2]. The clinical presentation of depressive cognitive disorder is inherently complex. Patients diagnosed with primary neurocognitive disorders may concurrently exhibit depressive symptoms, while individuals with mood disorders may present with prominent cognitive deficits. This bidirectional overlap complicates differential diagnosis and increases the risk of diagnostic error. Furthermore, neurocognitive and neuropsychiatric disorders often share symptom clusters, including impaired concentration, executive dysfunction, and psychomotor slowing, which further obscures clinical boundaries. Some investigators report that cognitive deficits associated with depressive states may persist despite adequate treatment of mood symptoms, remaining as residual impairments that affect daily functioning. However, the literature remains inconclusive regarding long-term outcomes. Evidence

*Corresponding author e-mail: shwikan@moh.gov.sa (Khalid Mohammed S. Alshwikan).
Receive Date: 07 December 2025, Revise Date: 29 December 2025, Accept Date: 31 December 2025

is mixed as to whether individuals with depressive cognitive disorder are at elevated risk for subsequent development of irreversible neurocognitive disorders or whether they generally demonstrate favorable recovery trajectories with appropriate intervention [3][4].

According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), diminished ability to think, concentrate, or make decisions constitutes one of the core diagnostic criteria for major depressive disorder. In older adults, cognitive complaints, particularly those involving memory, may be the primary presenting symptom. These complaints are frequently misattributed to degenerative conditions such as dementia, especially when affective symptoms are subtle or underreported. Cognitive function encompasses multiple domains, including memory, executive functioning, attention, and processing speed, each comprising distinct yet interrelated components. Impairment in one or more of these domains may significantly disrupt occupational performance, social engagement, and autonomy. Although certain longitudinal studies suggest that major depressive disorder may result in enduring cognitive deficits even after mood remission, findings across studies remain inconsistent and do not provide definitive conclusions regarding permanence or progression [5][6][7]. Depressive cognitive disorders are not confined to unipolar depression. They may also emerge within the clinical spectrum of bipolar disorder, particularly during depressive episodes, though cognitive disturbances can also occur during manic, hypomanic, or mixed states [3][8]. In such contexts, patients may exhibit disorientation, impaired attention, and short-term memory deficits that resemble neurodegenerative syndromes. The presentation of mania in older adults often differs from that observed in younger populations. Atypical features, including irritability, confusion, or cognitive slowing, may predominate, increasing the likelihood of misdiagnosis as dementia rather than mood disorder [9][10]. Accurate identification of depressive cognitive disorder is essential, as it carries important prognostic and therapeutic implications. Unlike primary neurodegenerative conditions, cognitive impairment secondary to mood disturbance may demonstrate partial or complete reversibility with timely and targeted psychiatric intervention. Differentiating between these entities requires comprehensive clinical evaluation, careful longitudinal observation, and consideration of psychosocial, medical, and neurobiological factors. Enhanced awareness among healthcare professionals is critical to reducing misdiagnosis and ensuring that patients receive appropriate, evidence-based care.



Fig. 1: Cognitive Disorders.

Etiology

Depression represents the leading cause of memory impairment among older adults and constitutes a major underlying factor in the development of depressive cognitive disorders. The etiology of these disorders is multifactorial and involves complex interactions among neurochemical, structural, endocrine, genetic, and psychosocial mechanisms. Understanding these contributing pathways is essential for accurate diagnosis and targeted therapeutic intervention. The neurotransmitter hypothesis provides a central framework for explaining both mood dysregulation and associated cognitive deficits. Serotonergic dysfunction has long been implicated in the pathophysiology of major depressive disorder, forming the scientific basis for pharmacologic treatments that target serotonin reuptake and receptor modulation. In particular, alterations in the serotonin 5-HT-1B receptor have been proposed as a significant factor in depressive disorders. Evidence demonstrates that dysfunction of 5-HT-1B receptors is present in the brains of individuals with depression, suggesting that impaired serotonergic signaling may disrupt neural circuits responsible for mood regulation and memory processing [11]. Such alterations may compromise synaptic plasticity and impair the consolidation and retrieval of information, thereby contributing to observable cognitive deficits. Structural and functional abnormalities within specific neurological pathways further explain the cognitive manifestations of depressive illness. Memory and learning depend upon integrated neural networks involving the amygdala and its connections with frontal and temporal lobe structures, including the medial temporal gyrus, prefrontal cortex, and anterior

cingulate cortex. Major depressive disorder has been shown to affect these regions, particularly the amygdala and hippocampus, both of which play critical roles in emotional regulation and declarative memory formation. Neuroimaging studies reveal volume reductions and altered activity patterns within these structures among depressed individuals. Damage or dysfunction in these areas interferes with verbal learning, memory encoding, and executive control, leading to the cognitive impairments characteristic of depressive cognitive disorders [12].

Neuroendocrine dysregulation also contributes substantially to pathogenesis. Chronic activation of the hypothalamic-pituitary-adrenal axis is frequently observed in depressive states, resulting in sustained elevations of cortisol levels. Hypercortisolemia exerts neurotoxic effects, particularly within the hippocampus, a region highly sensitive to glucocorticoids. Prolonged exposure to elevated cortisol has been associated with neuronal atrophy, reduced neurogenesis, and impaired synaptic connectivity. These structural alterations compromise cognitive performance, particularly in domains of memory and attention. The relationship between endocrine imbalance and hippocampal degeneration underscores the biological basis for cognitive decline in depressive disorders. Genetic susceptibility further modulates risk. Repeats in the C9ORF72 gene on chromosome 9 have been identified in patients with depressive cognitive disorders. This genetic variation has previously been linked to neurodegenerative dementias, suggesting overlapping molecular pathways between depressive cognitive impairment and degenerative processes. The presence of C9ORF72 expansions strengthens the hypothesis that certain individuals possess inherent vulnerability that predisposes them to both affective symptoms and cognitive decline [13]. Genetic predisposition may interact with environmental stressors to determine clinical expression. Psychosocial and environmental influences represent additional critical components in etiology. Exposure to psychological or physical abuse, inadequate social support, occupational loss, adverse life events, and substance misuse contribute to sustained stress responses. These stressors activate and dysregulate the hypothalamic-pituitary-adrenal axis, reinforcing neuroendocrine imbalance and perpetuating depressive symptomatology. Chronic stress impairs cognitive resilience and disrupts neural plasticity, thereby facilitating the emergence of cognitive deficits [14]. The etiology of depressive cognitive disorders therefore reflects a convergence of neurochemical imbalance, structural brain changes, hormonal dysregulation, genetic predisposition, and environmental stress. This multifaceted model highlights the necessity of comprehensive clinical evaluation that addresses biological, psychological, and social determinants to optimize patient outcomes.

Epidemiology

Major depressive disorder represents a significant public health concern among older adults, with reported prevalence rates ranging between 30% and 45% in this population. This substantial proportion underscores the clinical burden of depressive illness in late life and highlights its impact on healthcare systems. Among affected individuals, approximately 10% to 12% require admission to acute care facilities, while 12% to 14% are admitted to nursing homes, reflecting the severity of symptoms and associated functional decline [15]. These figures demonstrate the strong association between depressive disorders and increased healthcare utilization in geriatric populations. Cognitive impairment frequently accompanies depressive episodes in older adults. Studies indicate that cognitive deficits are present in 85% to 94% of individuals during an acute depressive episode, affecting domains such as memory, attention, executive functioning, and processing speed. Although cognitive performance often improves following remission of mood symptoms, residual deficits persist in a considerable proportion of patients. Between 39% and 44% continue to exhibit measurable cognitive impairment even after recovery from the acute episode [4]. This persistence suggests that depressive cognitive disorder may not be entirely reversible in all cases and raises questions regarding long-term prognosis and risk of progression. Conversely, depression is also common among individuals diagnosed with neurodegenerative dementia, occurring in approximately 15% to 23% of cases. This bidirectional relationship complicates differential diagnosis and clinical management. Executive function deficits are particularly prevalent, with research demonstrating a 20% to 30% occurrence among depressed individuals [16]. These impairments significantly affect independence, treatment adherence, and overall quality of life, reinforcing the need for early identification and comprehensive intervention strategies in older adults presenting with depressive and cognitive symptoms.

Pathophysiology

Depressive cognitive disorders arise secondary to an underlying neuropsychiatric condition, most commonly major depressive disorder. The clinical overlap between depressive syndromes and neurodegenerative dementias complicates identification of the precise mechanisms responsible for cognitive dysfunction. Shared manifestations such as memory loss, impaired concentration, psychomotor slowing, and executive dysfunction obscure diagnostic clarity and challenge clinicians attempting to distinguish functional from structural pathology. Despite this overlap, emerging evidence supports distinct neurobiological and cognitive patterns associated with depression-related cognitive impairment. Late-onset depression is frequently accompanied by measurable deficits across multiple cognitive domains. Memory impairment, including both anterograde and retrograde components,

represents one of the most extensively examined features in differentiating depressive disorders from primary dementias. In major depressive disorder, impairments are particularly evident in episodic memory, affecting explicit verbal and visual recall. In contrast, implicit memory functions tend to remain relatively preserved. This dissociation suggests that depressive cognitive impairment is not global but instead reflects dysfunction within specific neural systems. Temporal lobe abnormalities, especially involving hippocampal structures, have been implicated in this pattern of impairment. Functional and structural alterations within these regions disrupt encoding and consolidation processes necessary for efficient memory formation.

Circadian rhythm disturbances, commonly observed in depressive illness, may further contribute to cognitive decline. Sleep disruption altered melatonin secretion, and dysregulated cortisol patterns negatively influence hippocampal function and synaptic plasticity. These physiological disturbances impair attention, learning efficiency, and memory consolidation, thereby compounding cognitive deficits associated with mood disturbance. Comparative studies between depressive cognitive disorder and neurodegenerative dementia reveal important distinctions. Individuals with neurodegenerative dementia demonstrate a significantly accelerated rate of forgetting compared to both depressed patients and cognitively healthy individuals, who tend to forget information at comparable rates. Depressed patients often show more consistent, less random response patterns during cognitive testing. These findings suggest that the primary deficit in depression may involve impaired encoding rather than rapid storage decay. Current evidence does not support a single unified theory explaining cognitive impairment in depression; however, many investigations emphasize disrupted encoding processes as a central mechanism [17]. Cognitive dysfunction in depression is also influenced by psychological factors. Persistent negative automatic thoughts and rumination occupy attentional resources and interfere with active information processing. This cognitive interference reduces the efficiency of memory encoding and retrieval. Furthermore, diminished motivation and impaired concentration, core features of depressive illness, reduce the effort allocated to initial learning tasks. Insufficient cognitive engagement during acquisition leads to weaker memory traces and subsequent recall difficulties [16]. Collectively, the pathophysiology of depressive cognitive disorders reflects an interaction between neurobiological alterations in limbic and temporal structures, endocrine and circadian dysregulation, and maladaptive cognitive processes. This multifactorial model explains both the reversibility observed in many cases and the persistence of residual deficits in others.

History and Physical

Accurate evaluation of depressive cognitive disorders requires a comprehensive and methodical clinical assessment. The coexistence of depressive symptoms and neurocognitive impairment presents substantial diagnostic challenges. Several factors complicate assessment in individuals with dementia, including symptom overlap between depression and neurodegenerative disease, persistence of chronic behavioral changes, communication barriers in advanced stages, and variability in caregiver reporting. These elements necessitate a detailed history and a thorough mental status examination to achieve diagnostic clarity. Many depressive features overlap with manifestations of dementia. Reduced interest in previously pleasurable activities, disturbances in sleep patterns, appetite changes, psychomotor slowing or agitation, impaired concentration, and diminished energy may occur in both conditions. Because these symptoms are nonspecific, clinicians must carefully evaluate their onset, progression, and associated contextual factors. Particular attention should be directed toward identifying acute or subacute changes in behavior or mood, as sudden deterioration may indicate superimposed depression rather than gradual neurodegenerative progression. For example, worsening sleep disruption beyond expected circadian rhythm changes or a rapid decline in motivation may suggest an affective component. In advanced dementia, obtaining a reliable psychiatric history may be difficult due to aphasia, impaired comprehension, or reduced insight. Anosognosia, characterized by lack of awareness of cognitive deficits, further limits self-report reliability. In such circumstances, collateral information from caregivers becomes essential. However, caregiver reports must be interpreted cautiously. Caregivers often experience emotional strain, increased responsibility, and psychological distress, all of which may influence their perceptions and descriptions of the patient's symptoms. Notably, the presence of depression in patients with dementia has been strongly associated with caregiver burden and caregiver depressive symptoms, which may introduce reporting bias [16].

Historical features that raise suspicion for depression include expressions of hopelessness, helplessness, excessive guilt, death wishes, or suicidal ideation. Any indication of passive or active thoughts of death requires careful exploration to assess intent, planning, and immediate risk. Evaluation of suicide risk is mandatory in all patients who verbalize such thoughts, regardless of cognitive status. A prior personal history or family history of depressive disorder strengthens the likelihood of a current depressive episode. Behavioral signs observed during examination can provide additional diagnostic clues, particularly in individuals with severe cognitive impairment. Frequent moaning, a persistently sad facial expression, abrupt psychomotor changes, or episodes of screaming with depressive content may

signal underlying mood disturbance. Refusal to eat without clear medical explanation may also reflect depressive symptomatology. Patients with depressive cognitive disorder often present with prominent and distressing complaints of memory loss. Unlike certain neurodegenerative conditions, both recent and remote memory may appear equally affected, and language disturbances are typically absent. Beyond history, a structured mental status examination is essential. Assessment should include evaluation of mood, affect, thought content, cognition, insight, and judgment. Formal neurocognitive testing assists in delineating patterns of impairment and distinguishing encoding deficits from storage deficits. Laboratory investigations are necessary to exclude reversible medical causes such as metabolic abnormalities, endocrine dysfunction, nutritional deficiencies, or medication effects. A comprehensive approach that integrates clinical history, behavioral observation, cognitive assessment, and medical evaluation remains fundamental to differentiating depressive cognitive disorder from primary neurodegenerative disease and guiding appropriate management [16][17].

Evaluation

Comprehensive evaluation of depressive cognitive disorders extends beyond clinical history and mental status examination to include targeted laboratory investigations aimed at excluding reversible or secondary medical etiologies of cognitive impairment. A systematic diagnostic approach is essential to differentiate primary psychiatric causes from metabolic, infectious, nutritional, or paraneoplastic conditions that may present with similar neurocognitive manifestations. Laboratory assessments should therefore include screening for human immunodeficiency virus infection, syphilis, paraneoplastic syndromes, and deficiencies in vitamin B12 and folate, as these conditions may produce cognitive deficits that mimic depressive or neurodegenerative disorders. Identification and correction of such abnormalities are critical, as they may significantly alter prognosis and therapeutic strategy. Neuropsychological testing constitutes a central component of diagnostic clarification. Standardized instruments provide objective measurement across multiple cognitive domains and assist in distinguishing patterns of impairment characteristic of depressive disorders from those associated with dementia. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is widely utilized to evaluate immediate and delayed memory, attention, language, and visuospatial functioning [18]. Originally developed both to characterize dementia and to detect cognitive deficits across diverse clinical conditions, RBANS offers a structured profile of neurocognitive strengths and weaknesses. The Wechsler Memory Scale (WMS) further refines assessment by examining performance across seven distinct domains, including auditory memory, visual memory, visual working memory, and both immediate and delayed recall [19]. Additional screening tools, such as the clock drawing test and Trail Making Test, assess executive functioning, processing speed, and visuospatial organization, domains frequently affected in depressive cognitive disorders. These instruments facilitate differentiation between encoding deficits commonly observed in depression and the rapid forgetting patterns typical of neurodegenerative disease.

Neuroimaging studies may be indicated when structural or functional brain pathology is suspected. Magnetic resonance imaging provides detailed anatomical visualization to identify cortical atrophy, vascular changes, or focal lesions. Functional imaging modalities, including positron emission tomography and single-photon emission computed tomography, may reveal metabolic or perfusion abnormalities associated with dementia syndromes [8]. Although imaging findings in depressive cognitive disorder may be subtle, these modalities assist in excluding alternative neurologic diagnoses. Assessment of depressive symptom severity in individuals with cognitive impairment requires validated rating scales. The Cornell Scale for Depression in Dementia (CSDD) remains one of the most extensively employed instruments for this purpose. This nineteen-item scale integrates information obtained from both the patient and caregiver, thereby enhancing reliability in cases where self-report is limited. The CSDD evaluates mood-related symptoms, behavioral disturbances, physical signs, circadian variations, and ideational features, including suicidal thoughts and diminished self-worth. Scores exceeding ten suggest probable major depressive episode, while scores above eighteen indicate a definite major depressive disorder [20]. A multidimensional evaluation integrating laboratory studies, neuropsychological assessment, neuroimaging, and standardized rating scales ensures accurate diagnosis and supports the development of individualized treatment plans.

Treatment / Management

The management of depressive cognitive disorders requires an integrative approach encompassing pharmacological, non-pharmacological, and lifestyle interventions, tailored to the older adult population and patients with comorbid cognitive impairments. Pharmacological strategies constitute the mainstay of treatment, with selective serotonin reuptake inhibitors (SSRIs) widely regarded as first-line agents due to their favorable safety profile. SSRIs effectively mitigate depressive symptoms while minimizing the cholinergic adverse effects that can exacerbate cognitive impairment, a critical consideration in older adults with overlapping neurocognitive deficits. Common side effects observed in this population include hyponatremia, akathisia, reduced appetite, bradycardia, and gastrointestinal disturbances such as nausea, vomiting, or diarrhea. Additionally, anxiety, insomnia, and sleep pattern disturbances may occur, necessitating careful

monitoring during treatment [15]. For patients who exhibit insufficient response to SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs) serve as a secondary therapeutic option. Agents such as venlafaxine, desvenlafaxine, and duloxetine have demonstrated efficacy in ameliorating depressive symptoms while maintaining an acceptable safety profile for older adults. Commonly reported adverse effects include gastrointestinal discomfort, dizziness, insomnia, and constipation, which typically require dose adjustments or symptomatic management [15]. Tricyclic antidepressants, however, are generally contraindicated in patients with cognitive impairment due to their pronounced anticholinergic activity, which can exacerbate memory deficits and other cognitive disturbances.

Emerging pharmacological therapies also show promise for this population. Zolmitriptan, a 5-HT-1B receptor agonist, modulates serotonergic neurotransmission and has been found to alleviate both depressive symptoms and associated cognitive deficits. Its use in older adults may be limited by adverse effects including paresthesia and sedation [11]. Vortioxetine, a multimodal antidepressant with agonist activity at 5-HT1A receptors, partial agonism at 5-HT1B receptors, and antagonism at 5-HT3 receptors, has shown efficacy in improving depressive symptoms while concurrently enhancing cognitive performance, mirroring the tolerability profile of conventional SSRIs [4]. Furthermore, cholinesterase inhibitors such as donepezil, galantamine, and rivastigmine may be employed to address subsyndromal depression in patients with dementia, yielding dual benefits in ameliorating both cognitive dysfunction and behavioral disturbances [21]. Non-pharmacological interventions are equally critical, particularly in patients with treatment-resistant depression or those at heightened risk of adverse drug effects. Electroconvulsive therapy (ECT) has demonstrated substantial efficacy in improving both mood and cognition in older adults with depression and comorbid cognitive impairment. The risk of transient cognitive confusion can be mitigated by reducing ECT frequency to one or two sessions per week [22]. Psychosocial interventions, including interpersonal and behavioral therapies, have been associated with improvements in depressive symptomatology and quality of life for patients and caregivers alike. Caregiver-focused therapy plays a pivotal role, as familial burden and psychological distress can exacerbate patient symptoms, making their involvement essential in comprehensive management strategies. Lifestyle modifications serve as an adjunctive measure to pharmacological and psychosocial interventions. Dietary patterns consistent with the Mediterranean diet have been correlated with a lower prevalence of depressive symptoms, potentially mediated by anti-inflammatory and neuroprotective mechanisms. Physical activity, including moderate exercise, yoga, and meditation, contributes to the prevention and mitigation of depressive disorders, in part through upregulation of brain-derived neurotrophic factor, which supports neuroplasticity and cognitive function. Collectively, these interventions, when integrated into a structured, patient-centered care plan, provide a multidimensional framework for improving mood, cognitive function, and overall quality of life in individuals with depressive cognitive disorders.

Differential Diagnosis

Depressive cognitive disorders share overlapping clinical features with several neuropsychiatric and neurological conditions, making accurate differential diagnosis essential for effective management. Major depressive disorder represents a primary consideration, as cognitive deficits, particularly memory impairment, attention difficulties, and slowed information processing, are integral components of its clinical presentation [23]. In older adults, these cognitive impairments may precede or overshadow classic depressive symptoms such as low mood or anhedonia, further complicating the diagnostic process. Recognizing these deficits within the context of depressive episodes is critical to distinguishing depressive cognitive disorders from neurodegenerative processes. Neurodegenerative dementia constitutes another key differential diagnosis. Dementia is characterized by progressive deficits across multiple cognitive domains, including memory, executive function, language, and visuospatial abilities, often accompanied by behavioral disturbances such as agitation, apathy, and disinhibition. Unlike depressive cognitive disorders, which may show fluctuating or reversible cognitive impairment, dementia typically follows a steady, irreversible decline. Accurate diagnosis requires comprehensive neurocognitive testing, neuroimaging, and detailed history-taking to identify the pattern and trajectory of deficits, alongside evaluation of functional impairments in daily living activities. Late-onset bipolar disorder can also mimic depressive cognitive disorders or dementia. Patients may exhibit symptoms such as decreased need for sleep, distractibility, irritability, reduced energy, and diminished interest in previously pleasurable activities, which may be mistakenly attributed to cognitive decline or depressive episodes [8]. Careful assessment of mood history, episodic variations, and family psychiatric history is essential to differentiate bipolar spectrum disorders from depressive cognitive syndromes.

Delirium should be considered in cases of acute or subacute cognitive changes, particularly when precipitating factors such as medication effects, substance withdrawal, metabolic disturbances, or systemic infections are present. Delirium often presents with fluctuating attention, disorientation, and altered consciousness, features that help distinguish it

from more persistent depressive cognitive disorders [19]. Finally, other neurologic pathologies, including intracranial tumors, subdural hematomas, and normal pressure hydrocephalus, may present with cognitive deficits resembling depressive cognitive disorders. The temporal course, associated neurological signs, and radiologic findings are pivotal in identifying these conditions. Acute onset or focal neurological deficits, gait disturbances, or urinary incontinence may point toward an organic etiology, emphasizing the need for thorough neurologic evaluation alongside psychiatric assessment. Accurate differentiation among these conditions ensures targeted interventions and optimizes patient outcomes.

Prognosis

The prognosis of depressive cognitive disorders remains a subject of debate due to variability in outcomes and the potential for progression to irreversible neurodegenerative dementia. Evidence indicates that individuals with depressive cognitive disorders are at an elevated risk, approximately twice that of the general population, for subsequent development of dementia. Longitudinal studies spanning four to five years have demonstrated that over 70% of patients initially diagnosed with depression accompanied by cognitive impairment eventually progress to a formal diagnosis of dementia. Interestingly, approximately 18% of these patients had no observable cognitive deficits at the initial assessment, highlighting the insidious onset and potential under-recognition of cognitive decline in depressive disorders [24]. Several factors influence prognosis, including age at onset, severity and duration of depressive episodes, comorbid medical conditions, and response to treatment. Early detection and effective management of depressive symptoms may mitigate the trajectory of cognitive decline; however, residual cognitive impairments often persist despite successful treatment of mood symptoms. The presence of multiple depressive episodes or chronic depressive states further worsens outcomes, as repeated episodes may lead to structural and functional changes in the brain, particularly in the hippocampus and prefrontal cortex, which are critical for memory and executive function. Additionally, genetic predispositions, neuroendocrine alterations, and psychosocial stressors may modulate the risk of transition to dementia. Clinicians must consider that depressive cognitive disorders may exhibit heterogeneous outcomes. Some patients experience substantial improvement in cognitive performance with appropriate pharmacologic and non-pharmacologic interventions, while others show gradual and irreversible decline. Continuous monitoring, repeated neurocognitive testing, and individualized treatment strategies are essential to optimize outcomes and potentially delay the progression to neurodegenerative dementia. Understanding these prognostic factors allows healthcare providers to tailor interventions and provide informed guidance to patients and caregivers, balancing realistic expectations with therapeutic opportunities [24].

Complications

Depressive cognitive disorders are associated with significant functional and psychosocial morbidity. Cognitive deficits and depressive symptoms collectively exacerbate disability, impeding daily functioning and complicating management strategies. Individuals with coexisting depressive disorders and dementia experience more profound interference in routine activities, including self-care, social engagement, and occupational functioning, compared to those with either condition in isolation. This dual burden often results in prolonged hospitalizations and increased reliance on long-term care facilities, significantly elevating healthcare utilization and resource allocation [24]. Caretaker burden constitutes a major complication in managing patients with depressive cognitive disorders. Caregivers frequently face heightened responsibilities due to the complex behavioral and cognitive needs of affected individuals. Emotional strain, fatigue, and depressive symptoms are commonly observed among caregivers, which may, in turn, influence patient outcomes and quality of care. Additionally, depressive cognitive disorders are associated with increased prevalence of suicidal ideation, particularly among older adult populations, males, and socially isolated individuals. Contributory factors include medical comorbidities, functional decline, social withdrawal, and perceived hopelessness. Suicidal risk may be compounded in patients with dementia, as cognitive deficits impair judgment, problem-solving, and impulse control, necessitating vigilant monitoring and intervention. Beyond psychosocial complications, depressive cognitive disorders amplify the risk of medical comorbidities. Older adults with depression and cognitive impairment demonstrate higher incidence rates of cardiovascular disease, diabetes mellitus, and cerebrovascular events. The interplay between depressive symptomatology, cognitive decline, and physical health underscores the need for comprehensive, multidisciplinary care. Effective management requires not only pharmacologic and psychotherapeutic interventions but also structured support for caregivers, early identification of suicidal risk, and proactive monitoring of comorbid medical conditions [24].

Patient Education

The increasing proportion of older adults in the global population corresponds with a rising prevalence of mental health disorders, including depressive cognitive disorders, dementia, and late-onset depression. These conditions exert profound effects not only on affected individuals but also on their families and caregivers, contributing to diminished quality of life and increased caregiving responsibilities. The impact of depressive cognitive disorders extends to public health, as these conditions

significantly contribute to disability-adjusted life years within the elderly population. Early recognition and intervention are therefore critical to mitigating adverse outcomes [24]. Patient and caregiver education is a cornerstone in the prevention and management of depressive cognitive disorders. Knowledge of the characteristic symptoms, such as memory deficits, difficulty concentrating, mood disturbances, and functional impairment, enables individuals and caregivers to identify early warning signs and seek timely professional assistance. Education fosters adherence to treatment regimens, encourages lifestyle modifications, and supports the implementation of compensatory strategies to maintain independence and cognitive function. Moreover, effective education helps reduce stigma surrounding mental health conditions in older adults, promoting proactive engagement with healthcare services. Structured programs may include guidance on maintaining social connections, optimizing sleep hygiene, adhering to pharmacologic treatments, and participating in cognitive and physical activities that have demonstrated protective effects. Caregiver support programs are equally essential, as they provide strategies for coping with stress, preventing burnout, and enhancing patient outcomes. By empowering both patients and caregivers with knowledge and resources, early intervention becomes feasible, thereby reducing the likelihood of severe complications, functional decline, and risk of self-harm. In summary, education and preventive strategies are integral to the comprehensive management of depressive cognitive disorders, enhancing both individual and public health outcomes [24].

Enhancing Healthcare Team Outcomes

Depressive cognitive disorder represents a significant clinical challenge due to its complex presentation, overlapping with both neurocognitive and mood disorders. Patients frequently exhibit cognitive impairment alongside depressive symptoms, creating difficulties in distinguishing primary depression from neurodegenerative conditions. Early recognition and accurate diagnosis are critical for effective management, yet these processes often require the coordinated efforts of an interprofessional healthcare team. Comprehensive assessment involves detailed history taking, mental status evaluation, neurocognitive testing, and laboratory investigations, necessitating input from physicians, nurses, pharmacists, mental health and social specialists. Collaboration among healthcare providers is essential to optimize patient outcomes. Clinicians and pharmacists must carefully review medications to reduce the risk of drug-induced cognitive deficits or mood disturbances. Nursing staff provide continuous monitoring of cognitive and behavioral symptoms, ensuring adherence to treatment plans and facilitating early detection of symptom changes. Caregivers are integral to this process, offering critical insights into daily functioning, mood fluctuations, and behavior that may not be observable in clinical settings. Mental health professionals contribute by conducting thorough psychiatric evaluations, implementing individualized psychotherapeutic interventions, and supporting caregivers in behavioral management strategies. Interprofessional collaboration also improves the precision of therapeutic interventions. Coordinated communication ensures that pharmacologic treatments, such as antidepressants or cognitive enhancers, are appropriately selected and monitored, minimizing adverse effects while maximizing efficacy. Behavioral and environmental strategies can be integrated with pharmacologic approaches to address both cognitive and emotional symptoms. Structured team meetings and care planning sessions facilitate shared decision-making, align goals among providers, and reinforce caregiver education [22][23][24]. By fostering a collaborative environment, healthcare teams can achieve earlier diagnosis, individualized treatment, and continuous monitoring, ultimately enhancing the quality of care. Effective communication and coordinated interventions between clinicians, pharmacists, nurses, mental health specialists, and caregivers ensure that patients with depressive cognitive disorder receive comprehensive support, reducing the risk of complications, improving functional outcomes, and enhancing overall well-being.

Conclusion:

Depressive cognitive disorder represents a challenging clinical entity characterized by overlapping features of both mood disorders and neurodegenerative cognitive decline. The article emphasizes that although the condition often mimics dementia, it is frequently reversible when recognized early and treated effectively. However, the prognosis remains heterogeneous. A significant proportion of affected individuals show persistent cognitive deficits even after mood symptoms improve, and longitudinal studies suggest that many patients may eventually transition to irreversible dementias. This underscores the importance of continuous monitoring, repeated neurocognitive assessments, and individualized care plans. Effective management requires a multidisciplinary approach integrating pharmacological therapy, psychosocial support, cognitive rehabilitation, and lifestyle modification. SSRIs, SNRIs, and emerging serotonergic agents offer therapeutic benefit, while non-pharmacological interventions—such as electroconvulsive therapy, interpersonal therapy, and caregiver-focused strategies—play essential roles, especially in older adults or those with treatment-resistant symptoms. The article also highlights the substantial emotional and functional burden placed on caregivers, reinforcing the necessity for caregiver education and structured support systems. Ultimately, successful outcomes depend on early recognition, comprehensive

assessment, and coordinated interprofessional care. By adopting a holistic, patient-centered approach, clinicians can mitigate functional decline, enhance quality of life, and potentially delay the progression to neurodegenerative disease.

References:

1. Kiloh LG. Pseudo-dementia. Acta Psychiatr Scand. 1961;37(4):336-51.
2. Buccianelli B, Marazziti D, Arone A, Palermo S, Simoncini M, Carbone MG, Massoni L, Violi M, Dell'Osso L. Depression and Pseudodementia: Decoding the Intricate Bonds in an Italian Outpatient Setting. Brain Sci. 2023 Aug 13;13(8)
3. Elefante C, Brancati GE, Acierno D, Pistolesi G, Ricciardulli S, Weiss F, Romeo F, Lattanzi L, Maremmani I, Perugi G. Pseudodementia in Patients with Unipolar and Bipolar Disorders: A Case Series and Literature Review. J Clin Med. 2024 Mar 19;13(6)
4. Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019;15:1249-1258.
5. Hammar Å, Ronold EH, Rekkedal GÅ. Cognitive Impairment and Neurocognitive Profiles in Major Depression-A Clinical Perspective. Front Psychiatry. 2022;13:764374.
6. Heser K, Bleckwenn M, Wiese B, Mamone S, Riedel-Heller SG, Stein J, Lühmann D, Posselt T, Fuchs A, Pentzek M, Weyerer S, Werle J, Weeg D, Bickel H, Brettschneider C, König HH, Maier W, Scherer M, Wagner M., AgeCoDe Study Group. Late-Life Depressive Symptoms and Lifetime History of Major Depression: Cognitive Deficits are Largely Due to Incipient Dementia rather than Depression. J Alzheimers Dis. 2016 Aug 01;54(1):185-99.
7. Richly P, Abdulhamid P, Bustin J. [Depressive pseudodementia. Differential diagnosis or meeting point?]. Vertex. 2012 Nov-Dec;23(106):421-7.
8. Banga A, Gyurmey T, Matuskey D, Connor DF, Kaplan RF, Steffens DC. Late-life onset bipolar disorder presenting as a case of pseudo-dementia: a case discussion and review of literature. Yale J Biol Med. 2013 Jun;86(2):235-44.
9. Niizato K, Koto T. [Manic state and manic pseudodementia]. Nihon Rinsho. 2013 Oct;71(10):1781-6.
10. Kobayashi T, Kato S. Depression-dementia medius: between depression and the manifestation of dementia symptoms. Psychogeriatrics. 2011 Sep;11(3):177-82.
11. Afzal A, Ahmad S, Agha F, Batool Z, Tabassum S, Liaquat L, Sadir S, Nawaz A, Haider S. Administration of 5-HT-1B agonist ameliorates pseudodementia induced by depression in rats. Pak J Pharm Sci. 2018 Sep;31(5(Supplementary)):2179-2184.
12. Paula JJ, Miranda DM, Nicolato R, Moraes EN, Bicalho MA, Malloy-Diniz LF. Verbal learning on depressive pseudodementia: accentuate impairment of free recall, moderate on learning processes, and spared short-term and recognition memory. Arq Neuropsiquiatr. 2013 Sep;71(9A):596-9.
13. Bieniek KF, van Blitterswijk M, Baker MC, Petrucelli L, Rademakers R, Dickson DW. Expanded C9ORF72 hexanucleotide repeat in depressive pseudodementia. JAMA Neurol. 2014 Jun;71(6):775-81.
14. Vinet-Couchevellou M, Sauvagnat F. [Pseudodementia, what are we talking about? Part II: From Stertz to Alzheimer: A psychogenic disease after trauma]. Encephale. 2015 Jun;41 Suppl 1:S37-43.
15. Sekhon S, Patel J, Sapra A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 26, 2023. Late-Life Depression.
16. Kang H, Zhao F, You L, Giorgetta C, D V, Sarkhel S, Prakash R. Pseudo-dementia: A neuropsychological review. Ann Indian Acad Neurol. 2014 Apr;17(2):147-54.
17. Tripathi R, Mehrotra S. Pseudo-dementia: A neuropsychological review. Ann Indian Acad Neurol. 2015 Jan-Mar;18(1):123-4.
18. Sahin S, Okluoglu Önal T, Cinar N, Bozdemir M, Çubuk R, Karsidag S. Distinguishing Depressive Pseudodementia from Alzheimer Disease: A Comparative Study of Hippocampal Volumetry and Cognitive Tests. Dement Geriatr Cogn Dis Extra. 2017 May-Aug;7(2):230-239.
19. Vaish AK, Jain N, Gutch M, Yadav H. Pseudodementia due to intracranial tuberculomas: an unusual presentation. BMJ Case Rep. 2011 Dec 13;2011
20. Towsley G, Neradilek MB, Snow AL, Ersek M. Evaluating the Cornell Scale for Depression in Dementia as a proxy measure in nursing home residents with and without dementia. Aging Ment Health. 2012;16(7):892-901.
21. Laver K, Dyer S, Whitehead C, Clemson L, Crotty M. Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews. BMJ Open. 2016 Apr 27;6(4):e010767.
22. Rapinesi C, Serata D, Del Casale A, Kotzalidis GD, Mazzarini L, Fensore C, Carbonetti P, Scatena P, Capezzuto S, Moscati FM, Brugnoli R, Tatarelli R, Girardi P. Depressive pseudodementia in the elderly: effectiveness of electroconvulsive therapy. Int J Geriatr Psychiatry. 2013 Apr;28(4):435-8.
23. Tobe E. Pseudodementia caused by severe depression. BMJ Case Rep. 2012 Dec 14;2012
24. Gale SA, Acar D, Daffner KR. Dementia. Am J Med. 2018 Oct;131(10):1161-1169.